31.03.2024, 1321 Zeichen

Marinomed: Marinomed Biotech AG has entered into partnerships with GAIA Healthcare FZ LLC and VitaPlus Kft for the distribution of Carragelose nasal sprays. GAIA Healthcare, a renowned pharmaceutical marketing and distribution company based in the United Arab Emirates, has secured the rights to market two different Carragelose nasal sprays in the Gulf region. GAIA will be responsible for obtaining the regulatory approvals in the respective countries, envisaging a possible launch earliest in 2025. Furthermore, Marinomed has expanded its reach in selected Eastern European countries by entering a distribution partnership with VitaPlus, a Hungarian company owned by Belgium-based Ceres Pharma. VitaPlus is a leading Hungarian pharmaceutical company active in the development and distribution of innovative and value-for-money branded food supplements and medical devices in Hungary and beyond. VitaPlus brands such as Medistus® are well known by Hungarian pharmacists and consumers and very visible in Hungarian pharmacies and drugstores. VitaPlus is already driving pre-launch and marketing efforts of a Carragelose-containing nasal spray, planning the first sales as early as 2024.
Marinomed Biotech: weekly performance: 9.50%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (26/03/2024)

Christian Drastil: Wiener Börse Plausch

Wiener Börse Party #843: ATX zieht trotz S&P weiter, Indexfragen bei Erste und Immofinanz, Delisting für Ex-Do&Co-Bremse

Bildnachweis

Aktien auf dem Radar:Rosenbauer, EuroTeleSites AG, Strabag, Warimpex, Kapsch TrafficCom, Zumtobel, OMV, Österreichische Post, ATX, ATX Prime, ATX TR, Andritz, Erste Group, Uniqa, RBI, VIG, Mayr-Melnhof, Lenzing, DO&CO, Pierer Mobility, Porr, voestalpine, Austriacard Holdings AG, Marinomed Biotech, Gurktaler AG Stamm, Wienerberger, UBM, RHI Magnesita, Oberbank AG Stamm, Agrana, Amag.

---